Publication status
A preprint shares findings before peer review. Submission or review does not mean acceptance.
OBSERVATORY EVIDENCE
Examine approved ROP projects and the separately attributed scholarship of publicly associated Observatory members.
Authorship and professional affiliations do not imply Observatory ownership or institutional endorsement.
Initiative intelligence
This view connects approved ongoing work, public outputs, and current Network profiles for the selected program. A contributor affiliation is not presented as an institutional partnership.
Network intelligence
Current approved profiles explicitly connected to this program. Professional affiliation does not imply an institutional partnership.
Checking the governed Network registry…
Open the filtered Network directory →A preprint shares findings before peer review. Submission or review does not mean acceptance.
We distinguish governed projects, collaborations and independent scholarship by Network members.
Read the design, population, comparison and limitations alongside the numbers. Consult the full source.
Scientific evidence
Explore disclosed studies and their specific scientific relationship with microscopIA. Unverified outcomes are withheld.
A selection of microscopIA research, not the complete portfolio. Some governed projects are not displayed because of nondisclosure agreements or information-protection measures before publication.
Interpret findings alongside the study design, population and limitations. Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Curation and scientific governance →A percentage describes a proportion in the stated group. A risk ratio compares two risks: 1 means equal risks and 2 means twice the risk in the specified comparison. Association alone does not establish causation.
The estimated number of people treated for one additional benefit over a specified period and comparator. It depends on baseline risk and uncertainty.
Methods source ↗A quality-adjusted life-year (QALY) combines length and quality of life. Net monetary benefit values health gains at the stated threshold, then subtracts costs. A cost-effectiveness probability describes model uncertainty, not the probability that a patient improves.
Methods source ↗Read group order, units, design and follow-up with each estimate. Consult the source for confidence intervals and limitations.
Retinopathy of prematurity and health economics
This study evaluates the cost-effectiveness of topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity using multicenter real-world clinical and economic data from Colombia.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.
Record reviewed
Retinopathy of prematurity
This study evaluates real-world clinical outcomes associated with topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity across a multicenter care network in Colombia.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.
Observational estimate, not a randomized efficacy result.
Record reviewed
Retinopathy of prematurity and health economics
This study compares the cost-effectiveness of bevacizumab and ranibizumab for treatment-requiring retinopathy of prematurity using multicenter real-world clinical and economic data.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Observed retreatment after bevacizumab and ranibizumab, respectively.
Incremental net value favoring bevacizumab at the study threshold.
Share of probabilistic simulations favoring bevacizumab.
Record reviewed
Retinopathy of prematurity workforce and access
This study characterizes the distribution of the retinopathy of prematurity workforce in Colombia, evaluates geographic accessibility to care, and examines emerging practice patterns to identify gaps relevant to national service planning.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Record reviewed
Network intelligence
Associated members’ work is attributed to its authors and organizations. Records shown above as projects do not repeat here.
Checking member profiles and scholarship
Counts are not shown until the required records are available. This is not a zero-output result.
Browse the research catalogue →Discuss your question, available data and scientific decision. Scope and feasibility are assessed for each project; previous study findings do not guarantee outcomes for a new engagement.
Discuss a Research Project →Turn work into evidence
Strong collaboration begins with a worthwhile question, governed data, and a clear decision audience.